AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|
23.7 C
New York
Monday, September 14, 2026

Tag: technologies

Sunset World Group Trains Its Kitchen Staff in Cooperation with the German Organization Senior Expert Service

CANCÚN, Mexico, June 6, 2025 /PRNewswire/ -- Recently, the Culinary Team and kitchen staff at Sunset Royal and Sunset Marina hotels of the Sunset World...

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June 6, 2025 /PRNewswire/ -- Yesterday, NSCEB Vice Chair Michelle Rozo...

High Roller Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Las Vegas, Nevada, June 06, 2025 (GLOBE NEWSWIRE) -- High Roller Technologies (“High Roller” and the “Company”) (NYSE: ROLR), operator of award-winning premium online casino brands High Roller and Fruta, provides an update regarding the status of its ongoing compliance with the listing standards of the NYSE American.

essential COSTA RICA arrives at London Tech Week 2025 with a value proposition focused on innovation, sustainability, and investment

From digital solutions to real-world reforestation, Costa Rica arrives at London Tech Week 2025 with a national strategy aligned with the demands of the...

iOThree Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Singapore, June 06, 2025 (GLOBE NEWSWIRE) -- iOThree Limited ("iOThree" or the "Company") (NASDAQ: IOTR), a leading provider of maritime digital technologies including satellite connectivity and digitalization solutions in Singapore with a focus on facilitating the maritime industry towards digital transformation, today announced that it has received a written notification from the Nasdaq Stock Market LLC (“Nasdaq”) on June 3, 2025, indicating that the Company was not in compliance with the $1.00 closing bid price requirement for the last 30 consecutive business days from April 21, 2025 to June 2, 2025 under the Nasdaq Listing Rule 5550(a)(2).

Captivision, Inc. Announces Receipt of Staff Determination Letter from Nasdaq

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- Captivision Inc. (“Captivision” or the “Company”) (NASDAQ: CAPT), a pioneering manufacturer and global LED solution provider, announced that on June 4, 2025, it received a staff determination letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not regained compliance with the Market Value of Listed Securities (“MVLS”) Requirement by June 2, 2025. The Determination Letter has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s securities.

INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into EchoStar Corporation (SATS) and Encourages Investors with Substantial Losses or Witnesses with Relevant...

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar Corporation (NASDAQ: SATS) focused on whether EchoStar and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.

Genpact Limited Board Declares Quarterly Cash Dividend

NEW YORK, June 6, 2025 /PRNewswire/ -- Genpact Limited (NYSE: G), a global advanced technology services and solutions company, today announced that its board...

Opendoor Announces Preliminary Proxy Filing Seeking Approval for Discretionary Reverse Stock Split

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (Nasdaq: OPEN) (the “Company,” “Opendoor,” “we,” “our” or “us”), a leading e-commerce platform for residential real estate transactions, filed a preliminary proxy statement. The proxy statement was furnished in connection with the solicitation of proxies by Opendoor’s Board of Directors (the “Board”) for use at the Company’s Special Meeting of Stockholders to be held on Monday, July 28, 2025, at 9:30 a.m. Pacific Time.

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the closing of its previously announced non-brokered private placement for gross proceeds of $4,905,150 - consisting of $3,555,150 of Units and $1,350,000 of Debenture Units (each as defined below).

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company’s Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Hagen’s employment compensation and were granted as an inducement material to his acceptance of employment with TELA Bio.

Enovis to Participate in Upcoming Investor Conferences

Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), ein globales, im klinischen Stadium tätiges Onkologieunternehmen, das auf die Entwicklung neuartiger Krebstherapien wie Antikörper-Wirkstoff-Konjugate (AWK) (4174. TWO) spezialisiert ist, und TegMine Therapeutics, Inc. (TegMine), ein US-Biopharmaunternehmen, das erstklassige Antikörper entwickelt, die auf Krebsglykane und Glykoproteine abzielen, haben einen AWK-bezogenen Rahmendienstleistungsvertrag abgeschlossen.

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™

TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments (ADC) (4174. TWO), et TegMine Therapeutics, Inc. (TegMine), une entreprise biopharmaceutique américaine spécialisée dans le développement d’anticorps de premier ordre ciblant les glycanes et glycoprotéines tumoraux, ont conclu un accord-cadre de services (MSA) portant sur les ADC.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTechnologies